Vanguard Capital Management’s Mineralys Therapeutics MLYS Stock Holding History
Bought
Maintained
Sold
Other funds holding MLYS
Vanguard Capital Management's MLYS Position: Q3 2026 in Review
Vanguard Capital Management increased its Mineralys Therapeutics (MLYS) stake by 7.9% in Q3 2026, buying an estimated $5.92M and bringing the position to 2,974,139 shares worth $74.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1693.
Vanguard Capital Management first reported a position in MLYS in Q1 2026 and has held it in 3 quarters since. 219 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.
- Vanguard Capital Management held 2,974,139 shares of Mineralys Therapeutics worth $74.7M as of Q3 2026.
- Vanguard Capital Management bought 217,369 Mineralys Therapeutics shares in Q3 2026, an estimated $5.92M.
- Mineralys Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1693 holding.
- Vanguard Capital Management first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 219 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.